Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Evaluation of Society of Gynecologic Oncologists (SGO) ovarian cancer quality surgical measures.

Gogoi RP, Urban R, Sun H, Goff B.

Gynecol Oncol. 2012 Aug;126(2):217-9. doi: 10.1016/j.ygyno.2012.04.049. Epub 2012 May 3.

PMID:
22561039
2.

Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.

Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, Ferron G, Stoeckle E, Pomel C, Vinet B, Chereau E, Bergzoll C, Querleu D.

Int J Gynecol Cancer. 2012 Oct;22(8):1337-43.

PMID:
22964527
3.

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):287-92. Epub 2007 Nov 13.

PMID:
17996927
4.

Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Shih KK, Chi DS, Barakat RR, Leitao MM Jr.

Gynecol Oncol. 2010 Mar;116(3):364-9. doi: 10.1016/j.ygyno.2009.10.047. Epub 2009 Nov 7.

PMID:
19897231
5.

Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.

Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, Minig L, Biffi R, Radice D, Maggioni A.

Gynecol Oncol. 2010 Nov;119(2):259-64. doi: 10.1016/j.ygyno.2010.07.032. Epub 2010 Aug 25.

PMID:
20800269
6.

Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer.

Einenkel J, Ott R, Handzel R, Braumann UD, Horn LC.

Int J Gynecol Cancer. 2009 Oct;19(7):1288-97. doi: 10.1111/IGC.0b013e3181a3a833.

PMID:
19823067
7.

Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers.

Nezhat FR, Denoble SM, Cho JE, Brown DN, Soto E, Chuang L, Gretz H, Saharia P.

JSLS. 2012 Oct-Dec;16(4):511-8. doi: 10.4293/108680812X13462882736691.

8.

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2004 Sep;94(3):650-4.

PMID:
15350354
9.

The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.

Dewdney SB, Rimel BJ, Reinhart AJ, Kizer NT, Brooks RA, Massad LS, Zighelboim I.

Gynecol Oncol. 2010 Oct;119(1):18-21. doi: 10.1016/j.ygyno.2010.06.021. Epub 2010 Jul 31.

PMID:
20673970
11.

Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery.

Grabowski JP, Harter P, Buhrmann C, Lorenz D, Hils R, Kommoss S, Traut A, du Bois A.

Surg Oncol. 2012 Mar;21(1):31-5. doi: 10.1016/j.suronc.2010.08.006. Epub 2010 Sep 27.

PMID:
20875732
12.

Effect of surgical debulking on survival in stage IV ovarian cancer.

Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC.

Gynecol Oncol. 1997 Jan;64(1):4-8.

PMID:
8995539
13.

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR.

Gynecol Oncol. 2006 Nov;103(2):559-64. Epub 2006 May 22.

PMID:
16714056
14.

Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer.

Bashir S, Gerardi MA, Giuntoli RL 2nd, Montes TP, Bristow RE.

Gynecol Oncol. 2010 Nov;119(2):255-8. doi: 10.1016/j.ygyno.2010.07.017. Epub 2010 Aug 23.

PMID:
20739051
15.

The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.

Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, Gardner GJ, Leitao MM Jr, Levine DA, Sonoda Y, Abu-Rustum NR, Brown CL, Barakat RR.

Gynecol Oncol. 2010 Oct;119(1):38-42. doi: 10.1016/j.ygyno.2010.05.031. Epub 2010 Jul 6.

PMID:
20609464
16.

Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.

Chi DS, Barlin JN, Ramirez PT, Levenback CF, Mironov S, Sarasohn DM, Iyer RB, Dao F, Hricak H, Barakat RR.

Int J Gynecol Cancer. 2010 Apr;20(3):353-7. doi: 10.1111/IGC.0b013e3181d09fd6.

PMID:
20375796
17.

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.

Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY.

Gynecol Oncol. 1999 Mar;72(3):278-87.

PMID:
10053096
18.

The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian, fallopian tube, and primary peritoneal cancers.

Nezhat FR, DeNoble SM, Liu CS, Cho JE, Brown DN, Chuang L, Gretz H, Saharia P.

JSLS. 2010 Apr-Jun;14(2):155-68. doi: 10.4293/108680810X12785289143990.

19.

The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review.

Vernooij F, Heintz P, Witteveen E, van der Graaf Y.

Gynecol Oncol. 2007 Jun;105(3):801-12. Epub 2007 Apr 12. Review.

PMID:
17433422
20.
Items per page

Supplemental Content

Write to the Help Desk